Graftys Belgium, an innovative biotechnology company specialising in synthetic resorbable bone cements and based in Wallonia with a subsidiary in France, recently increased its capital with EUR 4.1 million from four investment funds – three Belgian and one French.
The group already markets its products in more than 20 countries, including the United States, Canada and Australia, and plans to market them in Asia, particularly in China, Japan and India.
The Eubelius team members involved in this transaction were David Szafran and Laurent De Pauw